Aranesp Versus Procrit: Amgen Will Submit Comparative Data to CMS

Amgen expects to present data demonstrating that front-loaded doses of the anemia agent Aranesp have advantages over standard doses of Johnson & Johnson's Procrit in cancer patients by year-end